Skip to main content

Month: January 2024

Banco Comercial Português, S.A. (“Bank”) informs about communication received from Chiado (Luxembourg) S.À.R.L regarding the sale of Bank shares through an Accelerated Bookbuilding process

Banco Comercial Português, S.A. (“Bank”) informs about communication received from Chiado (Luxembourg) S.À.R.L regarding the sale of Bank shares through an Accelerated Bookbuilding processAttachment2024 01 22 ABB Fosun EN

Continue reading

RJD Green Inc.’s Management Discusses 2023 Calendar Year-End Results and 2024 Growth Focus

TULSA, OK, Jan. 22, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – RJD Green Inc. (OTCPK: RJDG) CEO Ron Brewer updates shareholders on 2023 calendar year-end results and targeted 2024 growth. Dear Valued RJD Green Shareholders, As we have finished our 2023 calendar year and are moving into the 2024 year, RJD Green’s management team would like to take the opportunity to update all existing and potential shareholders with the latest information on developments with the Company. Please be advised – this letter is not a substitute for reviewing our press releases and SEC filings. Some of this update is opinion – please note the forward-looking statements disclosure. We wanted to simplify the complexity and put our latest news items in context and keep you updated on our activities and events that may not rise to the level of a press...

Continue reading

Viscosupplementation Market Size Worth USD 10.51 Billion in 2032 | Emergen Research

Increasing number of patients suffering from osteoarthritis and popularity of minimum invasive procedures and rapid advancements in development of therapies using hyaluronic acid are key factors driving viscosupplementation market revenue growth. Vancouver, Jan. 22, 2024 (GLOBE NEWSWIRE) — The global viscosupplementation market size reached USD 4.41 Billion in 2022 and is expected to register a revenue CAGR of 9.1% during the forecast period. Increasing number of patients suffering from osteoarthritis and popularity of minimum invasive procedures and rapid advancements in development of therapies using hyaluronic acid are key factors driving market revenue growth.   In addition, increasing number of sports-related injuries is another key factor driving revenue growth of the market. According to the data published by National Institute...

Continue reading

Rovio Entertainment Corp.: Sega Europe Limited has gained title to the minority shares in Rovio Entertainment Corporation, and the Rovio shares will be delisted from Nasdaq Helsinki

Rovio Entertainment Corporation        Stock Exchange Release        January 22, 2024 at 6.30 p.m. EET Sega Europe Limited has gained title to the minority shares in Rovio Entertainment Corporation, and the Rovio shares will be delisted from Nasdaq Helsinki Sega Europe Limited (“Sega”) has posted a security approved by the arbitral tribunal appointed by the Redemption Board of the Finland Chamber of Commerce in connection with the redemption proceedings concerning the minority shares in Rovio Entertainment Corporation (“Rovio”). Sega has thus gained title to all the shares in Rovio in accordance with Chapter 18, Section 6 of the Finnish Companies Act. After the security has been posted and the title to the minority shares transferred, the minority shareholders of Rovio being parties to the redemption proceedings are only entitled to receive...

Continue reading

Chicory Market Size Worth USD 1391.4 Million in 2032 | Emergen Research

Increasing need for chicory as a coffee alternative, rising demand for chicory in the nutraceutical and pharmaceutical industries, and technological advancements in the extraction and processing of high-purity chicory extracts are key factors driving chicory market revenue growth. Vancouver, Jan. 22, 2024 (GLOBE NEWSWIRE) — The global chicory market size was USD 739.6 million in 2022 and is expected to register a rapid revenue CAGR of 6.5% during the forecast period. Increasing need for chicory as a coffee alternative, rising demand for chicory in the nutraceutical and pharmaceutical industries, and technological advancements in the extraction and processing of high-purity chicory extracts are key factors driving market revenue growth. The rising number of diabetes patients is another key factor driving revenue growth of the market....

Continue reading

Music Licensing, Inc. (OTC: SONG) Achieves Milestone Royalty Payments, Unveils Aggressive Expansion Plan with $5,000,000 USD Music Intellectual Property Acquisition

Naples, Florida, Jan. 22, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG) proudly announces the reception of its inaugural royalty payments totaling $6,345.97 USD from globally renowned artists, including Elton John, Miley Cyrus, Lil Wayne, Lil Nas X, XXXTENTACION, and Halsey. This significant accomplishment marks a pivotal moment in the company’s trajectory, highlighting success in innovation and revenue diversification. Building on this success, Music Licensing, Inc. reveals its strategic plan to scale up through the acquisition of an additional $5,000,000 USD worth of Music intellectual property royalty stakes. This aggressive expansion aims to further solidify the company’s position in the industry and contribute to its ongoing success. With the anticipation of acquiring deals with similar metrics, Music...

Continue reading

BUREAU VERITAS – Number of shares and voting rights as of December 31, 2023

REGULATED INFORMATION Neuilly-sur-Seine, France – January 22, 2024 Information on number of shares and voting rights as stipulated by article 223-16 of the general regulations of the French financial markets authority AMF Issuer: Bureau VeritasDate Number of shares(1) Number of voting rights31/12/2023 453,871,520 Theoretical number of voting rights: 624,110,946 Number of exercisable voting rights: 623,870,261(1) including the new shares issued in Euroclear as a result of the exercise of stock options since January 1, 2023.                Bureau Veritas Head Office Tel: + 33 (0)1 55 24 70 00Société Anonyme Immeuble Newtime Fax: + 33 (0)1 55 24 70 01(Limited liability corporation) 40/52 boulevard du Parc www.bureauveritas.comShare capital of EUR 54,464,582.40 92200 Neuilly-sur-Seine  RCS Nanterre 775 690 621 France  ...

Continue reading

Disclosure of transactions in own shares from January 15th to January 19th, 2024

         Nanterre, January 22nd, 2024                      Disclosure of transactions in own shares from January 15th to January 19th, 2024 Within the framework of the authorization granted by the General Meeting of VINCI SA of April 13, 2023 to trade in its shares and in accordance with the regulations relating to share buybacks, VINCISA (LEI:213800WFQ334R8UXUG83) declares the purchases of treasury shares below (FR0000125486), carried out From January 15th to January 19th, 2024: I – Aggregate presentation by day and by marketIssuer’s name Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares in Euro Market (MIC code)           VINCI 15/01/2024 FR0000125486 1 069 116,04990 XPARVINCI 16/01/2024 FR0000125486 1 632...

Continue reading

Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer

Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of James Wentworth, PhD, MBA, as Chief Business Officer (CBO) and member of the executive management team, effective immediately. Dr. Wentworth will be responsible for developing, leading, and implementing Transgene’s business, corporate development and partnering strategies.  Alessandro Riva, MD, Chairman and CEO of Transgene, comments: “I am very pleased to welcome James, at a pivotal time for Transgene as we seek to develop novel cancer immunotherapies including an individualized neoantigen cancer vaccine. Our business development strategy will be crucial to achieving our goals, and James’ significant experience...

Continue reading

Update share buyback program (22 January 2024)

Update share buyback program (22 January 2024) Regulated information 22 January 2024 – 17.45 CET On 22 September 2023, Kinepolis Group announced the launch of its Share buyback program to cover share options. This program started on 25 September 2023 and ends on 24 March 2024 at the latest. Under this program, Kinepolis Group may buy back, through the appointed independent intermediary, up to 151,000 shares on Euronext Brussels for a total maximum amount of € 8 million. During the period from 15 January 2024 to 19 January 2024, the following transactions were carried out on Euronext Brussels under this program:Date Number of shares Average price (EUR)1 Lowest price (EUR) Highest price(EUR) Total(EUR)15/01/2024 1,400 € 43.70 € 43.60 € 43.80 € 61,180.0016/01/2024 5,000 € 41.93 € 40.50 € 42.85 € 209,652.5017/01/2024 1,750 €...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.